Angela Mastronuzzi: Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer
Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital, shared an article on LinkedIn:
“Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study” published with Cell Press is out.
We demonstrated an overall seroconversion rate of 76.6 % with a 100% seroconversion in HSCT. HM represents the most vulnerable group, with 33.3% who failed to induce any immunity. Finally, anti-RBD Abs quantification is not able to mirror the induction of a memory B- and T-cell immune response, essential for long-lasting protection. A combined immunological evaluation is necessary in frail populations to identify subjects at higher risk of severe COVID-19.
We thank the patients and families who took part in this study.”
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study.
Authors: Angela Mastronuzzi, et al.
Angela Mastronuzzi is the President of AIEOP. She is a pediatric hematologist-oncologist and the Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital (Italy). She is also a professor at the UniCamillus International Medical University, and a Board Member of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica). Her main fields of interest are CNS tumors and innovative therapies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023